Tumor necrosis factor-inducible gene 6 protein (TSG-6) (TSG-6)

Tumor necrosis factor-inducible gene 6 protein (TSG-6), also known as TNF-stimulated gene 6 protein, is a 35-38 kDa secreted glycoprotein that serves as a pivotal regulator of inflammation and extracellular matrix (ECM) remodeling [2.4.1, 2.4.3]. It is encoded by the TNFAIP6 gene and is rapidly induced by pro-inflammatory stimuli such as TNF-α and IL-1β in various cell types, including fibroblasts, chondrocytes, and mesenchymal stem cells (MSCs) [2.4.1, 3.3.2]. TSG-6 functions as a hyaladherin, binding to hyaluronan (HA) and forming complexes with inter-alpha-inhibitor (IαI) to stabilize the ECM and modulate the activity of various cytokines and chemokines [2.5.2, 3.3.3]. Its primary anti-inflammatory mechanism involves inhibiting the association of TLR4 with MyD88, thereby suppressing NF-κB signaling and promoting the polarization of macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype [2.2.1, 3.4.1]. Therapeutically, TSG-6 is a major mediator of the beneficial effects of MSC-based therapies and is being developed as a standalone biological agent for treating inflammatory and degenerative diseases [2.1.2, 3.2.1]. Recombinant human TSG-6 and its isolated Link module (Link_TSG6) have demonstrated efficacy in preclinical models of osteoarthritis, myocardial infarction, and corneal injury by reducing tissue damage and promoting repair [3.2.1, 3.2.3]. Despite its therapeutic potential, challenges such as a short plasma half-life and potential context-specific pro-fibrotic or oncogenic roles must be addressed [3.1.1, 3.3.4]. TSG-6 also serves as a valuable biomarker for predicting the efficacy of MSC preparations and monitoring disease progression in inflammatory conditions [2.1.2, 3.2.2].

Other names

TNFAIP6TNF-stimulated gene 6 proteinHyaluronate-binding proteinTNF alpha-induced protein 6TSG6Tumor necrosis factor alpha-induced protein 6

Agonism via recombinant protein administration, expression induction via kynurenic acid analogs, and neutralization via experimental antibodies; molecularly, it inhibits TLR4/MyD88 signaling and modulates ECM organization.